Visual acuity after proton beam therapy for uveal melanoma: development and validation of a prediction model
- 1Leiden University Medical Centre
Abstract
Aim To develop proton beam therapy treatment planning dose constraints for uveal melanoma (UM), more knowledge is needed on the impact of dose on toxicity. Here, we identify risk factors and develop prediction models for lower post-therapeutic visual acuity. Methods LUMC patients treated at Holland PTC between 2020-2023 (n=135) and at PSI between 1987-2019 (n=100) for UM were included. Candidate predictors for severe and moderate to severe vision impairment (Snellen <0.1 and <0.3) were established through literature review and expert interviews and selected through univariable analysis. Multivariable Cox models were fitted on a randomly selected 2/3rd of the combined dataset (n=156). Performance of both models was calculated on the training set and on the held-out validation set (n=79). Results The final models included baseline visual acuity, ciliary body dose and tumour location for both visual acuity cut-offs, supplemented by the optic disk dose and T-stage for visual acuity <0.1 and macula dose for visual acuity <0.3. Internal performance was good (c-indices 0.760 and 0.761 for visual acuity <0.1 and <0.3, respectively). In the held-out validation set, performance was acceptable (c-indices 0.657 and 0.689) and calibration was insufficient for the model predicting visual acuity <0.1, but acceptable for the model predicting visual acuity <0.3. Conclusion We developed a model predicting moderate to severe visual impairment with good internal performance and acceptable discrimination and calibration on a held-out test set. This is an important step towards NTCP modelling and the development of dose constraints for ocular proton therapy.
Related
- Development and Internal Validation of a Risk Prediction Model for Visual Impairment Progression in Elderly Patients with Diabetic Retinopathy: A Single-Center Retrospective Study.
- Development and validation of an AI-enhanced prediction model for 3-year visual decline in patients with diabetes using ophthalmic imaging: protocol for a real-world longitudinal cohort study
- Development and internal validation of a baseline prediction model for ≥10-point Oswestry Disability Index improvement by episode end among adults receiving outpatient physical therapy for low back pain : A retrospective cohort study
- Development and external validation of a risk prediction model for early peripheral intravenous catheter failure in outpatients and emergency department patients receiving consecutive infusion therapy.
- Development and internal validation of machine learning models for predicting lymph node metastasis in cutaneous head and neck melanoma
BibTeX
@misc{pors2026visual,
title = {{Visual acuity after proton beam therapy for uveal melanoma: development and validation of a prediction model}},
author = {L. Pors and M. Marinkovic and T. H. K. Vu and D. Mohabati and J. Bleeker and G. Luyten and A. Schalenbourg and A. Pica and J. Hrbacek and J.-W. Beenakker and C. Rasch and N. Horeweg},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.28.26366694},
url = {https://www.medrxiv.org/content/10.64898/2026.10.28.26366694v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Visual acuity after proton beam therapy for uveal melanoma: development and validation of a prediction model
AU - L. Pors
AU - M. Marinkovic
AU - T. H. K. Vu
AU - D. Mohabati
AU - J. Bleeker
AU - G. Luyten
AU - A. Schalenbourg
AU - A. Pica
AU - J. Hrbacek
AU - J.-W. Beenakker
AU - C. Rasch
AU - N. Horeweg
PY - 2026
DA - 2026/10/28
PB - medRxiv
DO - 10.64898/2026.10.28.26366694
UR - https://www.medrxiv.org/content/10.64898/2026.10.28.26366694v1
AB - Aim To develop proton beam therapy treatment planning dose constraints for uveal melanoma (UM), more knowledge is needed on the impact of dose on toxicity. Here, we identify risk factors and develop prediction models for lower post-therapeutic visual acuity. Methods LUMC patients treated at Holland PTC between 2020-2023 (n=135) and at PSI between 1987-2019 (n=100) for UM were included. Candidate predictors for severe and moderate to severe vision impairment (Snellen <0.1 and <0.3) were established through literature review and expert interviews and selected through univariable analysis. Multivariable Cox models were fitted on a randomly selected 2/3rd of the combined dataset (n=156). Performance of both models was calculated on the training set and on the held-out validation set (n=79). Results The final models included baseline visual acuity, ciliary body dose and tumour location for both visual acuity cut-offs, supplemented by the optic disk dose and T-stage for visual acuity <0.1 and macula dose for visual acuity <0.3. Internal performance was good (c-indices 0.760 and 0.761 for visual acuity <0.1 and <0.3, respectively). In the held-out validation set, performance was acceptable (c-indices 0.657 and 0.689) and calibration was insufficient for the model predicting visual acuity <0.1, but acceptable for the model predicting visual acuity <0.3. Conclusion We developed a model predicting moderate to severe visual impairment with good internal performance and acceptable discrimination and calibration on a held-out test set. This is an important step towards NTCP modelling and the development of dose constraints for ocular proton therapy.
ER -